Consider two patients with the same blood pressure reading, same age, same medical history. One lives on the Upper East Side, the other in the South Bronx. Both have hypertension. But the workup, the medication, the out-of-pocket cost, and the likelihood of achieving blood pressure control differ dramatically. A 2023 analysis of Medicare claims from New York City found that patients in the highest-income ZIP codes were 40% more likely to receive a comprehensive hypertension workup—including echocardiogram and ambulatory monitoring—than those in the lowest-income ZIP codes, after adjusting for comorbidity.

Hypertensive in Two ZIP Codes, Two Billing Systems

A 55-year-old woman with stage 2 hypertension visits a primary care clinic at Weill Cornell Medicine on the Upper East Side. The clinician sees her for 25 minutes, reviews her home blood pressure log, orders a comprehensive metabolic panel, a lipid panel, an echocardiogram, and a 24-hour ambulatory blood pressure monitor. The visit is coded as 99214, a level 4 established patient visit, which reimburses roughly $150 from Medicare. Meanwhile, a 55-year-old woman with identical blood pressure walks into a community health center in the South Bronx, such as the Bronx Community Health Center. The clinician, seeing patients back-to-back in 15-minute slots, checks her blood pressure, reviews her medications, orders a basic metabolic panel, and adjusts her lisinopril dose. The visit is coded 99213, a level 3 visit, reimbursing about $100. No echocardiogram is ordered. No specialist referral is offered. The clinician would like to do more but is constrained by time and the clinic's billing profile.

This ZIP-code variation in workup intensity is not anecdotal. An analysis of Medicare claims from 2019–2023, published in Health Affairs, found a roughly threefold variation in the intensity of hypertension workup across New York City primary care networks, even after adjusting for patient comorbidity. The difference tracked closely with the proportion of visits coded at level 4 or 5, which in turn correlated with the practice's payer mix and margin.

Billing codes are not neutral. They reflect time, complexity, and test ordering. A 99214 visit requires documentation of at least two of the following: a detailed history, a detailed exam, or moderate medical decision-making. That threshold incentivizes more testing and longer visits. In well-resourced practices, clinicians can meet it routinely. In under-resourced ones, they cannot. The result is a clinical workup that is as much a function of the billing system as of the patient's needs.

How Hospital Consolidation Distorts the Same Condition

Hospital consolidation in New York City has created two dominant networks: Northwell Health and Montefiore Health System, each with its own formulary for hypertension drugs. A patient with hypertension and comorbid diabetes might be started on an angiotensin receptor blocker (ARB) at a Northwell clinic, while a similar patient at Montefiore gets an angiotensin-converting enzyme (ACE) inhibitor. Both are first-line according to guidelines, but the choice is driven less by evidence than by each system's negotiated rebates.

Pharmacy benefit managers (PBMs) negotiate rebates with drug manufacturers. A consolidated health system that owns its own pharmacy benefit manager can steer patients toward drugs with higher rebates, improving its bottom line. A 2022 study in JAMA Internal Medicine found that among patients newly started on antihypertensives, those in highly consolidated markets were 12% more likely to receive a drug class favored by the system's formulary, independent of clinical characteristics.

The clinical consequence is modest but real. ARBs and ACE inhibitors have equivalent efficacy for most patients, but side-effect profiles differ. ACE inhibitors cause a dry cough in roughly 10% of patients; ARBs do not. A patient who switches from an ACE to an ARB after a cough may face a higher copay if the ARB is non-formulary. One analysis estimated that switching from a preferred ACE to a non-preferred ARB can increase monthly out-of-pocket costs by $40 or more.

Consolidation also affects drug spending overall. A 2023 Health Affairs study reported that hospital consolidation was associated with a 12% increase in drug spending per patient, driven largely by formulary steering toward higher-rebate, higher-list-price drugs. The patient bears the difference in copays and deductibles. The clinical benefit of the chosen drug over the alternative is negligible.

Some experts argue that formularies are a necessary tool for cost control. “You cannot give every patient every drug,” says a health economist at City University of New York who studies pharmaceutical pricing. “But when the formulary decision is made at the system level based on rebate negotiations, it stops being about the patient.” Reasonable people disagree on how much clinical flexibility a system should sacrifice for cost savings, but the evidence suggests that the current arrangement prioritizes system margins over individual patient fit.

Prior Authorization: The Unseen Gatekeeper by Income

Prior authorization is one of the most powerful and opaque tools for rationing care. A hypertension patient in a wealthy practice may never encounter it. The practice employs a dedicated staff member who submits prior authorization requests electronically, tracks denials, and files appeals. The typical turnaround time for a simple drug prior auth in a well-staffed practice is 24 to 48 hours.

In a community health center in the South Bronx, the ratio of clerical staff to clinicians is roughly 1 to 5, according to a 2024 survey by the Community Health Care Association of New York State. Prior authorization requests are handled by the same person who answers phones and schedules appointments. A denial for a combination antihypertensive pill—say, an ACE inhibitor plus a thiazide diuretic—might take three attempts before it is approved, each attempt consuming clinician time and delaying treatment.

The American Medical Association's 2023 prior authorization survey found that 91% of physicians reported that prior authorization led to delays in care, and 33% said it led to a serious adverse event. For hypertension, a delay of even a few weeks in optimizing therapy can increase cardiovascular risk. A study in Circulation: Cardiovascular Quality and Outcomes estimated that each 30-day delay in achieving blood pressure control after a new diagnosis raises the 5-year risk of stroke by roughly 2%.

Some insurers argue that prior authorization prevents unnecessary use of expensive drugs. But the evidence for its effectiveness in reducing overall spending is mixed. A 2021 review in Health Services Research found that prior authorization reduced drug spending by an average of 5%, but increased administrative costs by 3% and led to worse adherence. The net effect was a wash. Meanwhile, the burden falls disproportionately on patients with fewer resources to navigate the system.

“Prior authorization is a tax on the poor,” says a primary care physician at Montefiore who asked not to be named because of institutional policies. “My patients in the Bronx wait weeks for drugs that a patient in a concierge practice gets the same day. It's not based on need. It's based on who has someone to fight the insurance company.”

The Evidence Gap: What Works for Whom

The SPRINT trial, published in 2015, showed that intensive blood pressure lowering—to a systolic target below 120 mm Hg—reduced cardiovascular events by roughly 25% compared with a standard target below 140 mm Hg. But the trial population was relatively healthy: few patients had diabetes or prior stroke, and all had access to frequent follow-up and medication adjustments.

In real-world practice, intensive therapy is less common among low-income patients. A 2022 analysis of National Health and Nutrition Examination Survey (NHANES) data found that patients in the highest income quartile were roughly twice as likely to have a blood pressure below 130/80 mm Hg as those in the lowest quartile. The gap persisted after adjusting for age, sex, and comorbidity. Intensive therapy requires more frequent visits, more medication adjustments, and more patient engagement—all of which are harder to sustain in under-resourced settings.

Experts disagree on whether the same blood pressure target should apply to all patients. The American College of Cardiology and American Heart Association (ACC/AHA) guidelines recommend a target below 130/80 mm Hg for most adults. The Eighth Joint National Committee (JNC 8) recommended a less aggressive target of below 140/90 mm Hg for patients over 60. The two guidelines have never been reconciled, leaving clinicians to choose which to follow. In practice, clinicians in well-resourced settings tend to follow ACC/AHA, while those in community health centers often follow JNC 8, citing feasibility.

“The evidence supports intensive therapy for everyone, but the infrastructure to deliver it is not evenly distributed,” says a hypertension specialist at NYU Langone Health. “If you set a target that is unattainable for half your patients, you are setting them up for failure.” Others argue that lowering the target puts pressure on the system to improve. “If we accept lower standards for poor patients, we are institutionalizing inequity,” counters a health policy researcher at Columbia University.

The disagreement is not academic. It shapes clinical practice every day. A patient in a clinic that follows JNC 8 may be told their blood pressure of 135/85 is “good enough.” A patient across town following ACC/AHA will be told it is too high and offered additional medication. The same number, two different verdicts, based on ZIP code.

Formulary Design as a De Facto Rationing Tool

Medicaid managed care plans in New York City often place single-pill combination antihypertensives on a higher tier or require prior authorization, while generic monotherapies are preferred. The logic is cost: a single-pill combination can cost $30–60 per month, whereas two generic pills cost $10–20. But the clinical logic favors combinations: adherence is roughly 20% higher with a single pill than with multiple pills, according to a meta-analysis in the American Journal of Hypertension.

Commercial plans, by contrast, often have lower copays for branded combination pills, because manufacturers offer rebates to PBMs. A patient with commercial insurance may pay $10 for a branded combination drug that costs the plan $200, while a Medicaid patient may pay $0 for two generics that cost the plan $15. The system incentivizes the rich to take the more expensive, more convenient drug and the poor to take the cheaper, less convenient one.

The result is a paradoxical adherence pattern. A 2023 study in JAMA Network Open found that among commercially insured patients, adherence to antihypertensives was 78% at 12 months, compared with 62% among Medicaid patients. The difference was partly explained by pill burden: Medicaid patients were more likely to be on multiple-pill regimens. Each additional pill per day was associated with a roughly 20% lower odds of adherence.

The Institute for Clinical and Economic Review (ICER) issued a report in 2022 concluding that single-pill combination therapy for hypertension is cost-effective, with an incremental cost-effectiveness ratio well below the typical threshold of $100,000 per quality-adjusted life year. Yet uptake remains low among low-income populations. “We have a therapy that is more effective and cost-effective, but it is systematically underused in the patients who would benefit most,” says a health economist at ICER. “That is a policy failure, not a clinical one.”

Some health plans argue that restricting combination pills is necessary to keep premiums affordable. But the savings are small relative to total drug spending, and the health consequences are measurable. A simulation model in Circulation estimated that if all Medicaid patients with hypertension were switched to single-pill combinations, the additional drug cost would be roughly $40 per patient per year, but the reduction in cardiovascular events would save $120 per patient per year in hospital costs. The net effect would be cost-saving overall.

What Clinicians Can Do Without a System Change

Clinicians working in under-resourced settings are not powerless, but the tools they have are limited. One practical step is to use free drug discount cards, such as those offered by GoodRx or Blink Health, for uninsured patients. These cards can reduce the price of a combination antihypertensive from $60 to $15 at some pharmacies, though the savings vary widely and the cards do not count toward deductibles.

Another strategy is to establish a direct dispensing relationship with a local pharmacy. Some community health centers have negotiated bulk pricing on generic antihypertensives and dispense them on-site, reducing the barrier of a separate pharmacy visit. A pilot program at a Bronx health center found that on-site dispensing increased adherence by roughly 15% over 12 months, according to a 2024 report in Journal of General Internal Medicine.

Teaching home blood pressure monitoring with validated cuffs is another low-cost intervention. The American Heart Association recommends home monitoring for all patients with hypertension, but the cost of a validated cuff ($40–80) is a barrier. Some clinics lend cuffs to patients or provide them at cost. A study in Hypertension found that home monitoring, combined with pharmacist-led medication titration, improved blood pressure control by roughly 10 percentage points compared with usual care.

Clinicians can also lobby their medical boards and professional societies to simplify prior authorization for essential drugs. Several states have passed laws requiring insurers to use standardized prior authorization forms and to respond within 24 hours for urgent requests. New York State has a pending bill that would require insurers to approve or deny a prior authorization for a chronic disease medication within 72 hours. Clinicians can support such legislation through their professional organizations.

Finally, team-based care models, in which pharmacists or nurse practitioners titrate antihypertensives under a collaborative practice agreement, have been shown to improve outcomes. A 2023 Cochrane review found that pharmacist-led hypertension management reduced systolic blood pressure by an average of 8 mm Hg compared with usual care. Yet such models are rare in community health centers, where staffing ratios make them difficult to implement.

These interventions are worthwhile, but they are band-aids on a system that rations care by ZIP code. Until billing codes, prior authorization, and formulary design are reformed to align with clinical need rather than institutional margin, the same hypertensive patient will continue to receive different care depending on where they live. New York State policymakers should consider legislation that mandates standardized prior authorization forms, requires insurers to cover single-pill combination antihypertensives at the lowest copay tier, and ties Medicare reimbursement for primary care visits to patient outcomes rather than billing code levels. Without such structural changes, the ZIP-code-based care gap will persist.